A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting
Open accessThe DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
Ketamine, in research settings, rapidly reduces suicidal thoughts 2–24 h after a single infusion in patients with high suicidal ideation. In this study, the authors investigate ketamine’s effects on suicidality in a real-world sample of recent suicide attempters on a tertiary-care Consultation-Liaison (CL) psychiatry service. Using an open-label design, 16 transdiagnostic CL patients were recruited, 18–65 years old, to receive a single dose of intravenous ketamine (0.5 mg/kg) in the acute medical setting. All were psychiatrically hospitalized post-infusion. Baseline suicidality and depression measures were compared to ratings taken at 24 h, 5 days, 12 days, and 1, 3 and 6 months post-infusion using paired t-tests. Across all measures, rapid, statistically significant decreases (p’s < 0.001) were observed with large to very large effect sizes (Cohen’s d’s: 1.7–8.8) at acute timepoints (24 h; 5 days). These gains were uniformly maintained to 6 months post-infusion. Open-label ketamine appeared to rapidly and robustly reduced suicidal symptoms in an ultra-high-risk, heterogeneous, real-world sample. Ketamine infusion may therefore be a safe, feasible, viable method to rapidly reduce suicidality among medically hospitalized patients after a suicide attempt, with potentially enduring benefits. The current pilot findings suggest ketamine could be readily integrated into the settings where high-risk CL patients already receive healthcare, with the potential to become an important and novel tool in the treatment of suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous research echoes these results, with multiple studies finding high rates of remission for suicidal ideation after a single ketamine infusion in patients hospitalized for acute suicidal ideation [77][78][79].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Masters-level clinical raters with extensive training and experience in conducting depression treatment research administered the Montgomery–Asberg Depression Rating Scale (MADRS) [42] to assess total depression severity and severity of SI; the MADRS-SI item (item 10) and the Scale for Suicide Ideation (SSI; [43]; add…”
MethodRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 3×
“MADRS = Montgomery–Asberg Depression Rating Scale; SI = suicidal ideation; CSSRS = Columbia Suicide Severity Rating Scale; ASIQ = Adult Suicide Ideation Questionnaire; SSI = Scale for Suicide Ideation; QIDS-SR = Quick Inventory of Depressive Symptoms—Self-Report.”
Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research
Franklin, J. C., Ribeiro, J. D., Fox, K. R., Bentley, K. H., Kleiman, E. M., Huang, X., Musacchio, K. M., Jaroszewski, A. C., Chang, B. P., & Nock, M. K. (2017) · Psychological Bulletin · doi:10.1037/bul0000084 · Cited by 3,784 · cited 1×
“A prior suicide attempt is the single most important risk factor for suicide in the general population [1].”
BackgroundPsychological flexibility as a fundamental aspect of health
Kashdan, T. B., & Rottenberg, J. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.03.001 · Cited by 3,054
Nock, M. K., Borges, G., Bromet, E. J., Cha, C. B., Kessler, R. C., & Lee, S. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn002 · Cited by 2,897 · cited 2×
“The authors of this study use definitions of suicide, suicidal ideation and behaviors noted by Nock et al. 2008 [4].”
BackgroundMethodSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 1×
“, brain-derived neurotrophic factor (BDNF) expression and signaling) that damage plasticity, fostering neuronal atrophy and synaptic depression, particularly in the PFC and hippocampus [16,17].”
BackgroundNeural mechanisms of the cognitive model of depression.
Disner, S. G., Beevers, C. G., Haigh, E. A. P., & Beck, A. T. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3027 · Cited by 1,718
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 11
Making Progress in Clinical Trials for Suicide Prevention: A Review
Wilkinson, S. T., Bryan, C. J., Alphs, L. D., Canuso, C. M., Ostacher, M. J., Price, R. B., Bloch, M. H., Zarate, C. A., & Rhee, T. G. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4810 · Cited by 7
Self-citationNew pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality
Kotzalidis, G. D., Fiaschè, F., Alcibiade, A., Monti, L., Segni, F. D., Mazza, M., & Sani, G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2334425 · Cited by 4
“Among them, three included patients with various psychiatric disorders, including BD, but did not provide results separately for the BD group [60,64,73], another one probably included patients with BD, but did not report specific diagnoses, including patients with any depression [71].”
ResultTang, W., Jiang, W.-W., Que, W., Zhang, W.-Q., Chen, H.-L., & Zhou, L.-J. (2026) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796025100371 · Cited by 3
“…et al. , 2022; Hu et al. , 2016; Ionescu et al. , 2019; Kashani et al. , 2014; Keilp et al. , 2021; Murrough et al. , 2015; Pathak et al. , 2021; Phillips et al. , 2020; Price et al. , 2014; Shivanekar et al. , 2022; Sinyor et al. , 2018; Thakurta et al. , 2012; Zhou et al. , 2020, 2022).”
InfluentialAlgin, S., Banik, D., Rahman, S. A., Tusher, S. M., Johora, F. T., Akter, A., Ahmed, T., Biswas, M. A. M., Sinha, S., & Haque, M. (2024) · Cureus · doi:10.7759/cureus.57877 · Cited by 7
“Many similar earlier studies, including a meta-analysis, corroborate the result that continual sub-anesthetic ketamine infusions significantly and consistently reduce suicide ideation [84,85].”
ResultPsychedelics as a potential treatment for borderline personality disorder: A narrative review
Artna, E., Sandhu, G., Chisamore, N., Lipsitz, O., Kaczmarek, E. S., Johnson, D. E., Rosenblat, J. D., & Sediqzadah, S. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117152 · Cited by 1
The Effect of Ketamine infusions on suicidal ideation in various mood disorders
Mobin, M. B., Abid, Z., & Saqib, S. (2025) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.21482
Hu, B., Ortiz-Cruz, A., Sachidanandan, R. F., Ramiro, C., & Bourgeois, J. A. (2026) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2026.09.005
Metadata
- Authors
- Shivanekar, S., Gopalan, P., Pizon, A., Spotts, C., Cruz, N., Lightfoot, M., Rohac, R., Baumeister, A., Griffo, A., Panny, B., Kucherer, S., Israel, A., Rengasamy, M., & Price, R.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Price, Rebecca
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2022-10-24
- Volume
- 19
- Issue
- 21
- Pages
- 13792
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC9656070
- OpenAlex
- W4307160388
- Cited by
- 8
- References
- 76
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 1
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Laurel Zaks Memorial Research Award
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, suicide attempts, suicidality, suicidal ideation, psychosomatic medicine, inpatient psychiatric hospitalization, depression, rapid-acting antidepressants, real-world treatment
- MeSH terms
- Adolescent, Adult, Aged, Humans, Ketamine, Middle Aged, Pilot Projects, Suicide, Suicide, Attempted, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.